Hopp til innhold

Get alerts of updates about «Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment (ONTOX)»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment (ONTOX)

Project

Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment (ONTOX) - project description

Published Updated

ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon combination with tailored exposure assessment, will enable human risk assessment.


Summary

ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon combination with tailored exposure assessment, will enable human risk assessment.This strategy can be applied to any type of chemical and systemic repeated dose toxicity effect.However, for proof-of-concept purposes, focus will be put on 6 specific NAMs addressing adversities in the liver (steatosis and cholestasis), kidneys (tubular necrosis and crystallopathy) and developing brain (neural tube closure and cognitive function defects) induced by a variety of chemicals, including from the pharmaceutical, cosmetics, food and biocide sectors.The 6 NAMs will each consist of a computational system based on cutting-edge artificial intelligence (AI) and will be primarily fed by available biological/ mechanistic, toxicological/ epidemiological, physico-chemical and kinetic data. Data will be consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Data gaps, as identified by AI, will be filled by targeted state-of-the-art in vitro and in silico testing.The 6 NAMs will be evaluated and applied in collaboration with industrial and regulatory stakeholders in order to maximise end-user acceptance and regulatory confidence.This is anticipated to expedite implementation in risk assessment practice and to facilitate commercialisation.

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Hubert Dirven, Avdeling for miljø og helse, Norwegian Institute of Public Health

Project participants

Inger-Lise Karin Steffensen, Avdeling for miljø og helse, Norwegian Institute of Public Health
Birgitte Lindeman, Avdeling for miljø og helse, Norwegian Institute of Public Health
Oddvar Myhre, Avdeling for miljø og helse, Norwegian Institute of Public Health
Marcin Wlodzimierz Wojewodzic, Avdeling for miljø og helse, Norwegian Institute of Public Health

Start

01.05.2021

End

31.12.2026

Status

Active

Project owner/ Project manager

Norwegian Institute of Public Health

Project manager

Hubert Dirven